STAT July 12, 2024
Researchers were perplexed when the Food and Drug Administration announced it was investigating whether CAR-T therapy, one of the most effective treatments for blood cancers, could cause lymphoma. This was always a theoretical risk of genetically engineered therapies like CAR-T, but it never materialized in the decades after the technology’s birth.
So, when the agency pointed late last year to a couple dozen cases of T cell lymphoma in patients who had previously been treated with CAR-T cells, it felt like an old question had been reignited. The field jumped to investigate whether CAR-T truly could cause new cancers — and what the odds were if so. Those efforts have led to a “flurry of publications,” said Marcela Maus, a...
Today's Sponsors
Today's Sponsor